Nyrada Launches in vitro studies for brain injury program
- Nyrada (NYR) launches in vitro safety and toxicology studies as part of its brain injury program
- The company has been working to deliver an “optimal dose form” of its drug that will be suitable for intravenous administration
- The product has also been under evaluation through a preclinical stroke model, which was slated for the end of Q4 2022
- However, additional time was required to progress the formulation development work, resulting in a delay to the start of the stroke model study, with results now expected this quarter
- The platform last traded at 16 cents at 2:29 pm AEDT
